...
首页> 外文期刊>Influenza and other respiratory viruses. >Immunization with 1976 swine H1N1- or 2009 pandemic H1N1-inactivated vaccines protects mice from a lethal 1918 influenza infection.
【24h】

Immunization with 1976 swine H1N1- or 2009 pandemic H1N1-inactivated vaccines protects mice from a lethal 1918 influenza infection.

机译:1976年猪H1N1或2009年大流行H1N1灭活疫苗的免疫保护小鼠免受致命的1918年流感病毒感染。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Zoonotic infections with H1N1 influenza viruses that evolved initially from the 1918 virus (1918) and adapted to swine threatened a pandemic in 1976 (1976 swH1N1) and a novel reassortant H1N1 virus caused a pandemic in 2009-2010 (2009 pH1N1). Epidemiological and laboratory animal studies show that protection from severe 2009 pH1N1 infection is conferred by vaccination or prior infection with 1976 swH1N1 or 1918. OBJECTIVES: Our aim was to demonstrate cross-protection by immunization with 2009 pH1N1 or 1976 swH1N1 vaccines following a lethal challenge with 1918. Further, the mechanisms of cross-protective antibody responses were evaluated. METHODS: Mice were immunized with 1976 swH1N1, 2009 pH1N1, 2009 seasonal trivalent, or 1918 vaccines and challenged with 1918. Cross-reactive antibody responses were assessed and protection monitored by survival, weight loss, and pathology in mice. RESULTS AND CONCLUSIONS: Vaccination with the 1976 swH1N1 or 2009 pH1N1 vaccines protected mice from a lethal challenge with 1918, and these mice lost no weight and had significantly reduced viral load and pathology in the lungs. Protection was likely due to cross-reactive antibodies detected by microneutralization assay. Our data suggest that the general population may be protected from a future 1918-like pandemic because of prior infection or immunization with 1976 swH1N1 or 2009 pH1N1. Also, influenza protection studies generally focus on cross-reactive hemagglutination-inhibiting antibodies; while hemagglutinin is the primary surface antigen, this fails to account for other influenza viral antigens. Neutralizing antibody may be a better correlate of human protection against pathogenic influenza strains and should be considered for vaccine efficacy.
机译:背景:H1N1流感病毒的人畜共患性感染最初是从1918年的病毒(1918年)演变而来,并适应了猪的威胁,1976年爆发了大流行(1976 swH1N1),新型的重组H1N1病毒在2009-2010年(2009 pH1N1)引起了大流行。流行病学和实验室动物研究表明,接种1976 swH1N1或1918疫苗或事先感染,可以预防2009严重pH1N1感染。目的:我们的目标是证明通过在2009年pH1N1或1976 swH1N1疫苗致死性攻击后进行免疫接种可实现交叉保护。 1918.此外,对交叉保护性抗体应答的机制进行了评估。方法:用1976 swH1N1、2009 pH1N1、2009季节性三价或1918疫苗免疫小鼠,并用1918攻击。评估小鼠的交叉反应抗体反应,并通过存活,体重减轻和病理学监测其保护。结果与结论:1976 swH1N1或2009 pH1N1疫苗的免疫接种使小鼠免受1918年的致死性攻击,这些小鼠体重减轻,肺脏病毒载量和病理显着降低。保护可能是由于通过微中和试验检测到的交叉反应抗体。我们的数据表明,由于先前已使用1976 swH1N1或2009 pH1N1进行了感染或免疫,因此可能会保护普通人群免于将来发生类似1918年的大流行。另外,流感防护研究通常集中于交叉反应抑制血凝反应的抗体。尽管血凝素是主要的表面抗原,但这不能解释其他流感病毒抗原。中和抗体可能是人类针对致病性流感病毒株的更好保护,因此应考虑疫苗功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号